Concepts (87)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Triple Negative Breast Neoplasms | 6 | 2023 | 137 | 3.230 |
Why?
|
| Breast Neoplasms | 10 | 2023 | 2903 | 2.150 |
Why?
|
| Receptor, ErbB-2 | 4 | 2023 | 223 | 1.450 |
Why?
|
| Immunoconjugates | 1 | 2022 | 106 | 0.830 |
Why?
|
| Specimen Handling | 1 | 2021 | 98 | 0.770 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2020 | 16 | 0.760 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2020 | 35 | 0.760 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2020 | 292 | 0.700 |
Why?
|
| Neoadjuvant Therapy | 6 | 2023 | 318 | 0.690 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2020 | 93 | 0.690 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2019 | 18 | 0.690 |
Why?
|
| Pneumococcal Infections | 1 | 2019 | 46 | 0.670 |
Why?
|
| Neoplasm Staging | 5 | 2023 | 1939 | 0.590 |
Why?
|
| Patient Selection | 1 | 2020 | 686 | 0.570 |
Why?
|
| Internal Medicine | 1 | 2020 | 349 | 0.570 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2024 | 1204 | 0.560 |
Why?
|
| Biomarkers, Tumor | 1 | 2021 | 1464 | 0.450 |
Why?
|
| Humans | 21 | 2023 | 86678 | 0.440 |
Why?
|
| Female | 15 | 2023 | 44550 | 0.410 |
Why?
|
| Prognosis | 4 | 2023 | 3680 | 0.400 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2020 | 1075 | 0.400 |
Why?
|
| Internship and Residency | 1 | 2020 | 1010 | 0.390 |
Why?
|
| Antineoplastic Agents | 1 | 2022 | 2360 | 0.380 |
Why?
|
| B7-H1 Antigen | 2 | 2022 | 250 | 0.360 |
Why?
|
| Oropharyngeal Neoplasms | 2 | 2022 | 118 | 0.350 |
Why?
|
| Tumor Microenvironment | 2 | 2022 | 418 | 0.330 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 2262 | 0.310 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 1313 | 0.290 |
Why?
|
| Retrospective Studies | 5 | 2023 | 8496 | 0.290 |
Why?
|
| Immunotherapy | 2 | 2022 | 629 | 0.290 |
Why?
|
| Neoplasms | 1 | 2021 | 2898 | 0.280 |
Why?
|
| Middle Aged | 7 | 2023 | 25040 | 0.230 |
Why?
|
| Cohort Studies | 4 | 2023 | 2768 | 0.220 |
Why?
|
| Anthracyclines | 1 | 2022 | 37 | 0.220 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2023 | 468 | 0.210 |
Why?
|
| Hormones | 1 | 2022 | 141 | 0.210 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2022 | 2438 | 0.210 |
Why?
|
| Data Accuracy | 1 | 2021 | 31 | 0.200 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 2020 | 15 | 0.190 |
Why?
|
| Connecticut | 1 | 2020 | 27 | 0.190 |
Why?
|
| Shift Work Schedule | 1 | 2020 | 5 | 0.190 |
Why?
|
| Work Schedule Tolerance | 1 | 2020 | 36 | 0.190 |
Why?
|
| Software | 2 | 2024 | 654 | 0.180 |
Why?
|
| Automation | 1 | 2020 | 106 | 0.180 |
Why?
|
| Laryngeal Neoplasms | 1 | 2020 | 89 | 0.180 |
Why?
|
| Job Satisfaction | 1 | 2020 | 73 | 0.180 |
Why?
|
| United States | 3 | 2022 | 6681 | 0.180 |
Why?
|
| Combined Modality Therapy | 1 | 2023 | 1686 | 0.180 |
Why?
|
| DNA Mutational Analysis | 1 | 2021 | 526 | 0.180 |
Why?
|
| Disease-Free Survival | 1 | 2022 | 1204 | 0.180 |
Why?
|
| Tumor Burden | 1 | 2020 | 289 | 0.170 |
Why?
|
| Male | 5 | 2023 | 40988 | 0.170 |
Why?
|
| Neoplasm Grading | 1 | 2020 | 357 | 0.170 |
Why?
|
| Maxillary Sinus | 1 | 2019 | 26 | 0.170 |
Why?
|
| Immunohistochemistry | 1 | 2023 | 1753 | 0.170 |
Why?
|
| Streptococcus pneumoniae | 1 | 2019 | 48 | 0.170 |
Why?
|
| Papillomavirus Infections | 1 | 2022 | 239 | 0.170 |
Why?
|
| Mouth Neoplasms | 1 | 2020 | 194 | 0.160 |
Why?
|
| Carcinoma | 1 | 2022 | 436 | 0.160 |
Why?
|
| Machine Learning | 1 | 2020 | 232 | 0.160 |
Why?
|
| Age Factors | 1 | 2023 | 1852 | 0.160 |
Why?
|
| Bacteremia | 1 | 2019 | 99 | 0.160 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 860 | 0.160 |
Why?
|
| Clinical Trials as Topic | 1 | 2022 | 1169 | 0.150 |
Why?
|
| Lymph Nodes | 1 | 2020 | 533 | 0.150 |
Why?
|
| Logistic Models | 1 | 2020 | 1188 | 0.150 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 1384 | 0.130 |
Why?
|
| Mutation | 2 | 2023 | 3968 | 0.120 |
Why?
|
| Risk Assessment | 1 | 2021 | 2264 | 0.120 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 2504 | 0.110 |
Why?
|
| Breast | 2 | 2023 | 288 | 0.090 |
Why?
|
| Risk Factors | 1 | 2021 | 5420 | 0.090 |
Why?
|
| Aged | 2 | 2023 | 18423 | 0.070 |
Why?
|
| Computers | 1 | 2024 | 112 | 0.060 |
Why?
|
| Hydrodynamics | 1 | 2022 | 18 | 0.060 |
Why?
|
| Neoplasm, Residual | 1 | 2023 | 162 | 0.050 |
Why?
|
| Doxorubicin | 1 | 2022 | 295 | 0.050 |
Why?
|
| Papillomaviridae | 1 | 2022 | 153 | 0.050 |
Why?
|
| Health Status Disparities | 1 | 2023 | 170 | 0.050 |
Why?
|
| Kinetics | 1 | 2022 | 1513 | 0.040 |
Why?
|
| Precision Medicine | 1 | 2023 | 395 | 0.040 |
Why?
|
| Survival Rate | 1 | 2023 | 1864 | 0.040 |
Why?
|
| Contrast Media | 1 | 2022 | 1078 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2022 | 4214 | 0.030 |
Why?
|
| Adult | 2 | 2023 | 25659 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2022 | 7998 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2022 | 3362 | 0.020 |
Why?
|